Low-density lipoprotein apheresis: An overview

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 382-390

  Bambauer, Rolf ^a,b   Schiel, Ralf ^a   Latza, Reinhard ^a  

^a Institute for Blood Purification   (Germany)

^b NONE   (Germany)

Author keywords

Coronary heart disease; Familial hypercholesterolemia; Immunoadsorption; LDL hemoperfusion; Lipoprotein (a) apheresis; Liposorber system; Low density lipoprotein apheresis

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALLERGY; APHERESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; REVIEW; SHOCK; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DIET; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0042817882     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00070.x     Document Type: Review

References (84)

1. US Department of Health Education and Welfare. Report of the Working Group of Arteriosclerosis of the National Heart, Lung, and Blood Institute, US Department of Health Education and Welfare Publication No. (HIH) 82. Washington DC: US Government Printing Office, 1982.
2. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am J Cardiovasc 1992;70:733-7.
3. Heinonen OP, Huttunen JK, Manninen V et al. The Helsinki Heart Study: coronary heart disease incidence during extended follow-up. J Intern Med 1994;234:41-9.
4. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scand Simvastatin Survival Study (4s). Lancet 1994;344:1383-9.
5. Editorial. Design, rational, and baseline characteristics of the prospective pravastatin pooling (PPP) project - a combined analysis of three large-scale randomized trials. long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol andrecurrent events (CARE) and West of Scotland coronary prevention study (WOSCOPS). Am J Cardiol 1995;76:899-905.
6. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
7. Sachs FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:101-9.
8. Brown BG, Albers JJ, Fisher LD. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B (FATS). N Engl J Med 1990;32:1289-98.
9. Hjermann I, Holme I, Leven P. Oslo diet study and antismoking trial. Results after 102 months. Aro J Med 1986;80:701-11.
10. Huttunen JK, Manninen V, Mänttäri M. et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991;23:155-9.
11. Kannel WB, Casteli WP, Gtordon T, McNamanra PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971;74:1-12.
12. McGill HC. Persistent problems in the pathogenesis of atherosclerosis. Atherosclerosis 1984;4:443-51.
13. Brett AS. Treating hypercholesterolemia: how should practicing physicians interpret the published date for patients? N Engl J Med 1989;321:676-80.
14. Laaf A. Management of hypercholesterolemia: are preventive interventions advisable? N Engl J Med 1989;321:680-4.
15. Yudkin JS. How can be best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med 1993;306:1313-18.
16. Epstein FH. Beyond cholesterol. N Engl J Med 1989;320:915-24.
17. Stein Y, Stein O. Lipoproteins, cells and atheroma formation. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease-3. 3rd International Symposium. Munich 1990. Basel: Karger, 1992;9-16.
18. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
19. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
20. Levine GN, Keancy JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
21. Zimetbaum P, Frishman WH, Ooi WL et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. Arterioscler Thromb 1992;12:416-23.
22. LaRosa JC. Treatment of lipoproteins in elderly. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease, 4th International Symposium, Munich 1992. Basel: Karger, 1993;51-6.
23. Grundy SM, Vega GI, Bilheimer DM. Influence of combined therapy with mevinolin and interruption of bile-aced reabsorption on low density lipoprotein in heterozygous familial hypercholesterolemia. Ann Intern Med 1985;103:339-43.
24. Stein EA, Mieny C, Sitz L. Portocaval shunt in four patients with homozygous hypercholesterolima. Lancet 1975;1:832-5.
25. Buchwald H, Varco RL, Matts IP et al. Effect of partial heart bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias. N Engl J Med 1990;323:946-55.
26. Bilheimer DW, Goldstein VL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984;311:1658-64.
27. Illingworth DR, Bacon S. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arterioslcerosis 1989;9:1121-34.
28. Armstrong VW, Schleef J, Thiery J et al. Effect of HELP-LDL apheresis on serum concentrations of human lipoprotein (a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-40.
29. Bambauer R, Keller HE, Latza R et al. Three years experience with the liposorber system in hypercholesterolemia. In: Agishi T, Kawamura A. Mishima A, eds. Therapeutic Plasmapheresis, XII edn. Tokyo: VSP, 1993;415-20.
30. Bambauer R, Keller HE, Latza R, Schiel R. LDL apheresis in hypercholesterolemia with the liposorber system and immunoadsorption. Artif Organs 1994;18:121.
31. Schuff-Werner P, Gohlke H, Bartmann U et al. The HELP-LDL apheresis Multicenter Study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
32. Bambauer R, Schiel R, Keller HE, Latza R. LDL apheresis in two patients with extremely elevated lipoprotein (a) levels. Int J Artif Organs 1995;18:286-90.
33. Schiel R, Bambauer R, Müller UA. Treatment of severe hyperlipidemia: lipid-lowering drugs versus low density lipoprotein-apheresis. Eur Heart J 1995;16(Suppl.):230.
34. Schiel R, Bambauer R, Müller UA. Four years' treatment of patients with severe hyperlipidemia-lipid lowering drugs versus LDL apheresis. Int J Artif Organs 1995;18:5-12.
35. Rose GA, Blackburn H. Cardiovascular survey methods. WHO Monograph Series 1968;56:137-54.
36. DeGennes JL. Formes homozygotes cutaneo-tenineuses de xanthomastose hypercholesterolemique dans une observation familiale exemplaire. Essi de plasmapherese a titre de traitement heroique. Bull Mem Soc Med Paris 1967;18:1377-402 (in French).
37. Thompson GR, Kitano Y. The role of low-density lipoprotein apheresis in the treatment of familiar hypercholesterolemia. Ther Apher 1997;1:113-16.
38. Agishi T, Kaneko J, Hasuo Y et al. Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution. In: Sieberth HG, ed. Stuttgart: Schattauer, 1980;53-7.
39. Stoffel W, Borberg H, Grewe V. Application of specific extra-corporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 1981;2:1005.
40. Borberg H, Stoffel W, Oette K. The development of specific plasma immunoabsorption. Plasma Ther Transfus Technol 1983;4:459.
41. Wieland H, Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res 1983;24:904.
42. Nosé Y, Usami J, Malchesky PS et al. Clinical thermofiltration: initial application. Artif Organs 1995;19:425-7.
43. Mabuchi H, Michishita T, Mitsuaki T et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regeneraing unit (LDL-continuous apheresis). Atherosclerosis 1987;68:19-25.
44. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Org 1993;17:640-2.
45. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:in press.
46. Seidel D, Armstrong VW, Schuff-Werner P, for the HELP Study Group. The HELP-LDL apheresis multicenter study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 1991;21:375-83.
47. Jaeger BR, Meiser B, Nagel D et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96:II. 154-8.
48. Jaeger BR, Marx P, Pfefferkorn T, Hammann G, Seidel D. Heparin-mediated extracorporeal LDL/fibrinogen precipitation-HELP. Coronary and Cerebral Ischemia Acta Neurochir 1999;73(Suppl.):81-4.
49. Bambauer R, Schiel R, Latza R. Current topics on low-density lipoprotein apheresis. Ther Apher 2001;5:293-300.
50. Bosch T, Thiery J, Gurland HJ, Seidel D. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL apheresis and hemodialysis in patients with hypercholesterolemia and end-stage renal failure. Nephrol Dial Transplant 1993;8:1350-8.
51. Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:73.
52. Donner MG, Parhofer KG, Richter WO, Schwandt P. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism 1999;48:881-6.
53. Schettler V, Methe H, Schuff-Werner P, Müller GA, Wieland E. Acute effect of HELP treatment on radical scavering enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma. Eur J Clin Invest 2000;30:36-2.
54. Suckfüll M, Thiey J, Schorn K, Kastenbauer E, Seidel D. Clinical utility of LDL apheresis in the treatment of sudden hearing loss: a prospective, randomized study. Acta Otolaryngol 1999;19:763-6.
55. Borberg H. Results of an open, longitudinal multicenter LDL apheresis trial. Tranfus Science 1999;20:83-94.
56. Pokrovsky SN, Adamova IY, Afanasieva OY, Venevolenkskaya GF. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study Artif Organs 1991;15:136-9.
57. Pokrovsky SN, Sussekov AV, Afanasieva OI, Adamaova IY, Laykishev AA, Kukharchuk VV. Extracorporeal Immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis): preliminary clinical data. Chem Phys Lipids 1994;67/68:323-30.
58. Ullrich H, Lackner KJ, Schmitz G. Lipoprotein (a) apheresis in severe coronary heart disease: an immunoadsorption method. Artif Organs 1998;22:135-9.
59. Yamamoto A, Kawaguchi A, Harada-Shiba M, Tsushima M, Kojima S. Apheresis technology for prevention and regressions of atheroslcerosis: an overview. Ther Apher 1997;1:233-41.
60. Agishi T, Wood W, Gordon B. LDL apheresis using the Liposorber LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;55:879-904.
61. Kroon AA, Aengevaeren RM, van der Werf T et al. LDL apheresis Atherosclerosis Regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
62. Gordon BR, Saal SD. Clinical experience and future directions for low-density lipoprotein apheresis in the United States. Ther Apher 1997;1:1249-352.
63. Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: Clinical result. Ther Apher 1997;1:242-8.
64. Gordon BR, Kelsey SF, Bilheimer DW et al. for the Liposorber Study Group. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1992;70:1010-16.
65. Daida H, Lee YL, Yokoi H et al. Prevention of restenosis after percutaneous translminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994;73:1037-40.
66. Thompson GR, Maher VM, Matthews S et al. Familial hypercholesterolemia regression study: Arandomized trial of low-density liposprotein ahperesis. Lancet 1995;346:811-16.
67. Kroon AA, Aengevaeren RM, van der Werf T et al. LDL-apheresis Atherosclerosis Regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
68. Mabuchi H, Koizumi J, Shimizu M et al. and the Hokuriku-FH-LDL apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998;82:1489-95.
69. Nishimurra S, Sekiguchi M, Kano et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan low-density lipoprotein apheresis coronary athererosclerosis prospective study (L-CAPS). Atherosclerosis 1999;144:409-17.
70. Bosch T, Schmidt B, Kleophas W et al. LDL hemoperfusion: a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with whole human Blood. Artif Organs 1997;21:977-82.
71. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion: a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 1997;21:1060-5.
72. Jansen J, Banyai S, Schmaldienst S et al. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL apheresis system for the treatment of familial hypercholesterolemia. Wien Klin Wochenschr 2000;112:61-9.
73. European Atherosclerosis Society Study Group. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88.
74. Olbricht CJ, Schamann D, Fischer D. Anaphylactoid reactions. LDL apheresis with dextran sulphate ACE Inhibition. Lancet 1992;340:908-9.
75. Kroon A, Moim J, Stabenhoff AFH. ACE Inhibitors and LDL apheresis with dextran sulfate absorption. Lancet 1992;340:1476-9.
76. Keller C. LDL apheresis with dextran sulphate and anaphylactoid reaction of ACE inhibitors. Lancet 1993;341:60-1.
77. Smith GD, Shipley MJ, Marmot MG, Rose GR. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992;267:70-6.
78. Tait G. Cholesterol reduction and regression of coronary atherosclerosis: The Coronary Atheroma Regression study. In: Gordon BR, ed. The Treatment of Severe Hypercholesterolemia: Can We Impact Disease Course? Princeton, NJ: Excerpta Medica, 1992;83-9.
79. Tatami R, Inoue N, Itoh H. Regression of coronary atherosclerosis by combined LDL apheresis and lipid-lowering drug therapy in patients with familial hyperchlesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
80. Kitabake A, Sato H, Hori M. Coronary atherosclerosis reduced in patients with familial hyperchotesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. Clin Ther 1994;16:416-28.
81. Nishiura S. L-CAPS Group Regression of coronary artery disease in familial hypercholesterolemia; Japan LDL apheresis Coronary Atherosclerosis Prospective Study (L-CAPS), L-CAPS Group, Department of Cardiology, Yokohama Rosal Hospital. Ther Apher Dial 2003;7:in press.
82. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
83. Treasure CB, Klein JO, Weintraub WS. Beneficial effects of cholesterol-lowering therapy On the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
84. Levine GN, Keancy JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.